04:20 PM EDT, 09/15/2025 (MT Newswires) -- Avidity Biosciences ( RNA ) said Monday it closed its underwritten public offering of nearly 17.3 million shares, including about 2.3 million shares sold under the underwriters' full exercise of an option to buy additional shares, at $40 per share, for gross proceeds of $690 million.

The company said it intends to use the net proceeds, together with cash and marketable securities, to advance three late-stage clinical programs, build commercial inventory to support potential launches, expand commercial infrastructure, progress research and development of its AOC platform, and for working capital and general corporate purposes.